GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Long-Term Capital Lease Obligation

Cellectis (LTS:0WA2) Long-Term Capital Lease Obligation : €39.38 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cellectis Long-Term Capital Lease Obligation?

Cellectis's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €39.38 Mil.

Cellectis's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 (€42.60 Mil) to Sep. 2023 (€41.06 Mil) and declined from Sep. 2023 (€41.06 Mil) to Dec. 2023 (€39.38 Mil).

Cellectis's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€63.30 Mil) to Dec. 2022 (€46.59 Mil) and declined from Dec. 2022 (€46.59 Mil) to Dec. 2023 (€39.38 Mil).


Cellectis Long-Term Capital Lease Obligation Historical Data

The historical data trend for Cellectis's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Long-Term Capital Lease Obligation Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.89 62.28 63.30 46.59 39.38

Cellectis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.59 45.10 42.60 41.06 39.38

Cellectis  (LTS:0WA2) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Cellectis Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cellectis's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (LTS:0WA2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (LTS:0WA2) Headlines

No Headlines